BMS and Prime ink potential $3.5bn deal to develop T cell therapies
Bristol Myers Squibb (BMS) has agreed to a research and licensing deal with Prime Medicine to develop ex vivo T…
Bristol Myers Squibb (BMS) has agreed to a research and licensing deal with Prime Medicine to develop ex vivo T…